| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3951097 | Gynecologic Oncology Reports | 2015 | 5 Pages |
Abstract
•Bevacizumab was an effective agent in one case of advanced uterine PNET.•VEGF was expressed by the tumor, supporting a mechanism for effectiveness.•Cisplatin/etoposide/bevacizumab should be further studied in clinical trials.•Patient remains disease-free forty-eight months following intervention.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jorge Novo, Pincas Bitterman, Alfred Guirguis,